The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 51-year-old female with recurrent major depressive disorder achieved full remission on escitalopram 20 mg daily three years ago after her third depressive episode. She has been in sustained remission with PHQ-9 scores consistently between 2 and 4 at quarterly visits. Over the past eight weeks, she has experienced gradually worsening low mood, anhedonia, fatigue, and difficulty concentrating, with her PHQ-9 rising to 14. She reports no identifiable stressors, no changes in medical health, and no new medications. Her thyroid studies are normal, and she denies substance use. She takes no other medications that interact with CYP2C19 or CYP3A4. She has been fully adherent to escitalopram as confirmed by pharmacy records and expresses frustration that her medication has stopped working. Her previous two depressive episodes each responded initially to different SSRIs before losing efficacy after two to three years, requiring medication switches. The PMHNP is evaluating whether this presentation represents antidepressant tachyphylaxis. Which of the following best represents the appropriate evaluation?
Explanation
Antidepressant tachyphylaxis is characterized by gradual loss of efficacy during maintenance treatment in the absence of identifiable precipitants or pharmacokinetic changes. The evaluation should distinguish this pattern from naturalistic recurrence by examining the timeline, absence of precipitants, and cross-medication pattern, then follow a sequential approach of dose optimization before mechanistic class switching.
Key Takeaway
A repeated pattern of gradual SSRI loss of efficacy after sustained remission across multiple medications, without identifiable precipitants or pharmacokinetic changes, is suggestive of antidepressant tachyphylaxis and should prompt systematic evaluation including dose optimization before considering mechanistic class switching.